$QNTA conference call breakdown: Key topics that were discussed:
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 some Paxlovid users had symptoms relapse, versus with escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<<
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 explains COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 *** FDA strategy summarized
“Actively working to completely FDA process”
*** Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 “Shared CEO” position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ
- roles of co-ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination of research to where qnta is now and moving forward toward to a continued path to achieving goals
ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.
